Vyvanse provided consistent efficacy in pediatric patients at each timepoint measured, from 1.5 to 13 hours postdose1
INDICATION AND LIMITATION OF USE
Vyvanse (lisdexamfetamine dimesylate) is indicated for the treatment of ADHD in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.
Primary Endpoint: SKAMP-D time of onset2
- 1.5 hours postdose (P<.005 for Vyvanse vs placebo)
Key Secondary Endpoint: SKAMP-D duration of efficacy (measured at 1.5, 2.5, 5, 7.5, 10, 12, and 13 hours postdose)2,3
- Significant improvement in least squares mean SKAMP-D scores for Vyvanse vs placebo at all postdose timepoints measured (P<.005)
SKAMP-D subscale: validated classroom assessment tool that measures behavior problems leading to classroom disruptions. It is not a measure of classroom or academic performance.
Duration of effect was not systematically evaluated in patients aged 13-17.
Read full study details